Skip to content
Home/Companies/Biotech/Orchard Therapeutics

Orchard Therapeutics

Biotech·UK·Exited 2018·Held 1yr
Entry
2017
Hold
1yr
Exit
2018

Who owns Orchard Therapeutics?

Orchard Therapeutics is a British Biotech company, formerly owned by 4Bio Partners, exited in 2018 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-07-08

Open JSON · CC-BY
4Bio Partners
Investor
4Bio Partners
4BIO Ventures III · 2022 · Life Sciences VC

Key facts

HQUK
SectorBiotech
StatusAcquired
Exit Type
IPO
Exit Year
2018

More from 4BIO Ventures III

Other portfolio companies in the same fund.

Aptadir Therapeutics
Active
BiotechItaly· 2026
Cloverleaf Bio
Active
BiotechUnited States· 2026
Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
Actithera
Actithera
Active
BiotechSwitzerland· 2025
Hornet Therapeutics
Active
BiotechUK· 2024
March Biosciences
March Biosciences
Active
BiotechUS· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Orchard Therapeutics?

Orchard Therapeutics was formerly owned by 4Bio Partners, exited in 2018. No current private equity owner is on file.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue